Candel Therapeutics stock up 172% after Phase III prostate cancer success
The company’s stock price soared after its prostate cancer drug CAN-2409, met the primary endpoint in a Phase III study.
12 December 2024
12 December 2024
The company’s stock price soared after its prostate cancer drug CAN-2409, met the primary endpoint in a Phase III study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.